Reported 10 days ago
Bristol Myers Squibb's stock is experiencing a significant rise following FDA approval of its new schizophrenia drug, marking the first innovative treatment for the condition in three decades. Analysts discuss the drug's mechanism and its potential impact on the market.
Source: YAHOO